American Society of Hematology Meeting

Abstract Presentation

William P. Vaughan, MD, MBA
Director, Bone Marrow Transplantation Program

At the 43rd ASH Annual Meeting in Orlando this December, I will present the results of a 3-year study for allogeneic matched related donor transplantations (“mini-transplants”) conducted here at UAB.

Findings: MRD Allo transplantation using a large volume leukopheresis product mobilized with G-CSF

Inside This Issue

1 American Society of Hematology Meeting
1 Getting To Know Us
1 Referring Physicians – Special Thanks
2 The Bone Marrow Angels of Alabama
2 Bone Marrow Transplant Centers Conference
3 Gleevec
4 Diseases and Treatment Options
4 Future Issues

Referring Physicians
Special Thanks

We are very grateful to all of our referring physicians. We appreciate their trust and confidence and pledge to always provide the highest quality of care to their patients. In addition, we are ready to provide information on new...
American Society of Hematology Meeting continued from page 1

and decadron, pharmacokinetics directed modest dose intravenous Busulfan plus fludarabine conditioning, and long MTX/CSA results in sustained engraftment, low 30 day mortality, and low incidence of severe GVHD.

The key to this approach is to recognize that the intensity of the preparatory regimen needs to be tailored to the individual disease, stage, and patient condition not just the maximum tolerated or minimal sufficient intensity.

Bone Marrow Transplant Centers Conference November 16, 2001

The first regional Bone Marrow Transplantation Affiliation meeting will be held November 16, 2001 at the University of Alabama at Birmingham Hospital, WP 302 conference room. The Event will begin at 1:00 PM and will continue throughout the afternoon ending with a seminar & dinner at Ruth’s Chris restaurant Embassy Suites.

This event has been certified for 3 hours in Category 1 credit and is sponsored by The Division of Continuing Medical Education of the University of Alabama School of Medicine.

CME objectives
- Describe current autologous transplant treatment strategies
- Identify the risks associated with treatment of multiple myeloma patients
- Explain the quality management practices for bone marrow transplant patients
- Recognize requirements for effective bone marrow transplantation program support

Physicians currently involved in transplantation or planning to develop transplant capability are invited to attend but space is limited. For information please call Rick Carroll at (205) 975-5713.

Bone Marrow Angels of Alabama

Linda Johnson, a 27-year-old mother of 3 children, discovered she had chronic myelogenous leukemia (CML). Linda worked as an office manager for an auto dealer in northern Alabama. She underwent a bone marrow transplant in the spring of 1999. During this process she had numerous setbacks due to graft versus host disease and multiple infections. Linda had to use her savings to provide for her children during this time and had no immediate family to provide emotional or financial support. Her car note became past due and was repossessed by the finance company and her children did not have presents for their birthdays or at Christmas time. She faced a long recovery period at home with no income to rely on.

Linda’s story is a composite of some of the challenges that face patients’ undergoing bone marrow transplantation. At the Bone Marrow Transplantation Unit at UAB Hospital in Birmingham, patients from all over the southeast are accepted for bone marrow transplantation and receive high quality compassionate medical care. However, every year there are Linda’s who are at risk of dying of complications or suffering long term financial and social losses because of inadequate personal, financial and emotional support systems.

The Bone Marrow Angels of Alabama Foundation was started this year by Ed Reifenberg of Montgomery to help the Lindas undergoing transplants at UAB. Ed was diagnosed with Waldenstrom's macroglobulinemia ten years ago and received many courses of chemotherapy. When he developed myelodysplastic syndrome he underwent an allogeneic bone marrow transplant at UAB from his HLA identical sister and now is likely cured of both of his diseases. He is back at work and enjoying his wife and family, but he was touched by the plight of others with less social, financial and family support and has given of his time and money to help them in this way. Ed is a recipient of the Alabama Division of the American Cancer Society Lifetime Achievement Award.

William P. Vaughan, MD, MBA
care for transplant patients, quality of life after marrow transplantation and management of the marrow transplant team. Dr. Salzman has been with the UAB BMT Program since January 1995. She is Director of Medical Services for the BMT Program and has an NIH grant to study HPV reactivation and broad GYN health issues following bone marrow transplantation. She has published in the areas of supportive care and lymphoma management. She has taken the initiative to develop a clinical research effort in multiple myeloma centered within the BMT Program at UAB. Consequently we are now performing autologous and Allogeneic transplants for several patients per month with this disease.

Referring Physicians
Continued from page 1

medical procedures, research protocols, and CME opportunities. Also, referring physicians and health professionals can call the medical information service 24-hours a day, 7-days a week for consultations, and information.

Nationwide
1-800-UAB-MIST
(1-800-822-6478)
Birmingham Metropolitan Area
934-6478

A trained health-services representative will route your call to the appropriate UAB physician or other health-care specialist.

Bone Marrow Transplantation Program

Pediatric referrals (205) 939-6721
Kathy Langley, RN (Coordinator)

or

(ask to speak with the following directly)
Dr. William Vaughan  Dr. Donna Salzman
Dr. Richard Lopez  Dr. Alejandro Garcia

Questions or Comments?
Please send your questions or comments regarding this newsletter to Rick Carroll email: rcarroll@uabmc.edu
The UAB Bone Marrow Transplantation Program has performed 724 transplants for these diseases as of September 30, 2001.

### Diseases and Type of Transplant

<table>
<thead>
<tr>
<th>Diseases</th>
<th>Type of Transplant</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute and Chronic Leukemias</td>
<td>2, 3</td>
</tr>
<tr>
<td>Aplastic Anemia</td>
<td>2</td>
</tr>
<tr>
<td>Myelodysplastic Disorders</td>
<td>2,3</td>
</tr>
<tr>
<td>Myeloproliferative Disorders</td>
<td>2,3</td>
</tr>
<tr>
<td>Multiple Myeloma</td>
<td>1</td>
</tr>
<tr>
<td>Malignant lymphomas including HD</td>
<td>1,2,3</td>
</tr>
<tr>
<td>Breast Cancer</td>
<td>1</td>
</tr>
<tr>
<td>Oligodendroglioma</td>
<td>1</td>
</tr>
<tr>
<td>Multiple Pediatric Diseases</td>
<td>1,2,3</td>
</tr>
</tbody>
</table>

### Type of Transplant

<table>
<thead>
<tr>
<th>Type of Transplant</th>
<th>Donor</th>
<th>Graft</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.AUTO</td>
<td>SELF</td>
<td>Bone marrow, Peripheral blood</td>
</tr>
<tr>
<td>2.ALLO:</td>
<td>MRD (Matched related donor)</td>
<td>Bone marrow, Peripheral blood</td>
</tr>
<tr>
<td></td>
<td>MUD: (Matched unrelated donor)</td>
<td>Bone marrow, Cord blood</td>
</tr>
<tr>
<td></td>
<td>Haplo identical related donors</td>
<td>Bone marrow, Peripheral blood</td>
</tr>
<tr>
<td>3.&quot;MINI&quot; TRANSPLANTS</td>
<td>MRD</td>
<td>Bone marrow, Peripheral blood</td>
</tr>
</tbody>
</table>

**January 2002**

- UAB – BMT Outcomes review
- ASH review
- Meet Dr. Richard Lopez
- Your ideas